Retatrutide Brand Name, Manufacturer and FDA Status (2026)
Direct answer: Retatrutide does not have an official brand name. Eli Lilly and Company is the sole manufacturer, and the drug currently goes by its research compound code LY3437943. A trademarked brand name will be announced only when Lilly files its NDA with the FDA -- which has not happened as of early 2026.
Quick Stats
| Stat | Detail |
|---|---|
| Manufacturer | Eli Lilly and Company (NYSE: LLY) |
| Research Code | LY3437943 |
| Phase 3 Weight Loss | Up to 26.6% body weight (TRIUMPH-4) |
| FDA Status | Investigational -- NDA not yet submitted (as of Q1 2026) |
| Mechanism | Triple agonist: GIP + GLP-1 + glucagon receptors |
Key Takeaways
- Eli Lilly is the sole manufacturer of retatrutide -- the same company that made Mounjaro and Zepbound
- The drug's official research name is LY3437943 -- no brand name has been announced yet
- Retatrutide is in Phase 3 trials under the TRIUMPH clinical program, with multiple studies reporting positive data in 2025--2026
- Phase 3 results show up to 26.6% average body weight loss -- the highest ever recorded in a late-stage obesity trial
- Lilly's track record with tirzepatide gives real insight into how approval, pricing, and access might unfold
- FDA approval is not expected before late 2026 at the earliest, and 2027 is more realistic
Knowing who makes a drug might sound like a trivial detail. But when you are tracking something that could genuinely change how obesity is treated, the manufacturer's history shapes everything -- from how fast approval moves to whether your insurance will actually cover it. Lilly is not a newcomer here. They have already navigated this exact road with tirzepatide.
Here is everything you need to know about Eli Lilly's role in retatrutide's development, what the drug is called, and what happens next.
What Is Retatrutide Brand Name? The Direct Answer
The question "what is retatrutide brand name" comes up often, and the answer is straightforward: there is no brand name yet.
When people search for the retatrutide brand, they typically find the drug's research designation -- LY3437943 -- which is Eli Lilly's internal compound code, not a commercial name. Brand names are only assigned during the NDA filing process, which Lilly has not initiated for retatrutide as of early 2026.
For comparison: tirzepatide's research designation was LY3298176 for years before Lilly gave it the commercial names Mounjaro (for type 2 diabetes) and Zepbound (for obesity). Retatrutide will follow the same path. The retatrutide brand name will emerge when Lilly prepares its regulatory submission -- not before.
Until then, the correct terms to use are: retatrutide, LY3437943, or Eli Lilly retatrutide.
Retatrutide Brand: What to Expect When Lilly Names It
The retatrutide brand will be assigned by Eli Lilly during the FDA New Drug Application (NDA) process — most likely in 2026 or 2027 — and will almost certainly follow the same dual-brand pattern Lilly used for tirzepatide. Expect two separate brand names for retatrutide: one for the obesity indication and a different one for type 2 diabetes.
Predicted Retatrutide Brand Naming Pattern
Based on how Lilly named tirzepatide (Mounjaro for T2D, Zepbound for obesity) and how Novo named semaglutide (Ozempic for T2D, Wegovy for obesity, Rybelsus for the pill), the retatrutide brand strategy is likely to follow the same template:
| Indication | Expected Retatrutide Brand Name Style | Real Examples From the Class |
|---|---|---|
| Obesity / chronic weight management | Punchy 2–3 syllable consumer brand | Wegovy, Zepbound |
| Type 2 diabetes | Medical-feeling 3-syllable brand | Ozempic, Mounjaro |
| Oral version (if pursued) | Distinct, easier-to-pronounce | Rybelsus |
The retatrutide brand names themselves haven't been published or trademarked publicly yet. Watch the USPTO trademark database in late 2026 for the first signals — Lilly typically files trademarks 6–12 months before a brand launch.
Why the Retatrutide Brand Name Matters
The brand name affects:
- Insurance coverage codes — brand-specific PA criteria
- Patient assistance program eligibility — savings cards apply per brand
- Cash-pay direct programs — LillyDirect lists by brand
- Off-label vs on-label prescribing — obesity brand cannot be prescribed for diabetes and vice versa, even though it's the same molecule
- Search and marketing visibility — brand searches dominate volume once approved
Until the retatrutide brand is announced, "retatrutide" remains the only correct term to use in prescriptions, insurance discussions, and patient communications.
Who Makes Retatrutide? Meet Eli Lilly
Eli Lilly and Company is an Indianapolis-based pharmaceutical company with over 145 years in the business. They are behind Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (also tirzepatide) for obesity.
Lilly did not stumble into GLP-1 drugs. They built their GLP-1 franchise deliberately, starting with dulaglutide (Trulicity) in 2014, then advancing to tirzepatide's dual GIP/GLP-1 mechanism. Retatrutide is the next evolution -- a triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors simultaneously.
That triple mechanism is what separates it from anything currently on the market. Semaglutide (Wegovy/Ozempic) acts on one receptor. Tirzepatide acts on two. Retatrutide acts on three, and the Phase 3 data suggests that extra lever produces meaningfully greater weight loss. For a deeper look at the science, see our guide on what is retatrutide.
Lilly's Track Record: Why It Matters
Lilly has already done the GLP-1 approval process twice -- Mounjaro was approved for type 2 diabetes in 2022, Zepbound for obesity in November 2023. They understand the FDA's expectations, they have established manufacturing infrastructure, and they have real-world data on what it takes to bring a GLP-1 class drug to market at scale.
That matters for three specific reasons:
Speed. Lilly already has relationships with FDA reviewers who know their safety and efficacy data submission format. That does not mean shortcuts, but it does mean fewer back-and-forth delays.
Manufacturing. One of the biggest bottlenecks after Mounjaro approval was supply. Lilly was caught somewhat flat-footed and had to ramp manufacturing capacity quickly. They have since invested billions in new facilities specifically to avoid a repeat with the next generation of drugs.
Insurance access. The pattern with tirzepatide was frustrating -- initially limited coverage, slow formulary decisions, high out-of-pocket cost. Lilly launched patient savings programs and pushed back on insurance denials with clinical data. Expect a similar playbook with retatrutide, but with more leverage now that Lilly's obesity drugs are established in the market.
The TRIUMPH Clinical Program Explained
Lilly named their Phase 3 retatrutide program TRIUMPH -- a suite of large clinical trials studying retatrutide across different patient populations.
The trials that have reported data or are underway include:
- TRIUMPH-4 (completed, Dec 2025): Tested the two highest doses in adults with obesity and knee osteoarthritis. Results: average weight loss up to 26.6% at the higher dose -- the most weight loss ever documented in a Phase 3 obesity trial. Knee pain also improved significantly.
- TRANSCEND-T2D-1 (Phase 3, Mar 2026): Evaluated retatrutide in adults with type 2 diabetes. Lilly reported positive topline results showing statistically significant reductions in both HbA1c and body weight.
- TRIUMPH-1 and TRIUMPH-2: Testing retatrutide in broader obesity populations, with results expected mid-2026.
- TRIUMPH-8: Currently recruiting adults with obesity or overweight (NCT07232719).
The breadth of these trials is deliberate. Lilly wants approval across multiple indications -- not just obesity, but diabetes, cardiovascular disease, and osteoarthritis. That expands the potential patient base significantly and strengthens the case for insurance coverage.
What the Phase 3 Data Actually Shows
The numbers coming out of the TRIUMPH trials are remarkable, even by the high standards that Mounjaro already set.
TRIUMPH-4 results, announced December 2025: up to 71.2 lbs average weight loss at the highest dose in adults with obesity. On a placebo-adjusted basis, body weight decreased by 26.6%. For context, semaglutide (Wegovy) produces around 15% weight loss, and tirzepatide (Zepbound) achieves up to 22.5%.
Phase 2 data published in the New England Journal of Medicine (2023) showed 24.2% weight loss at 48 weeks -- already the highest ever reported for a single-agent obesity medication at the time.
The TRANSCEND-T2D-1 results from March 2026 showed retatrutide significantly lowered HbA1c in people with type 2 diabetes, alongside meaningful weight reduction.
One important caution: TRIUMPH-4 data identified a new safety signal called dysesthesia -- an abnormal sense of touch -- in some participants. It has not been seen at this magnitude in earlier trials. Lilly is monitoring it closely, and it may factor into the FDA review timeline.
How Does Retatrutide Compare to Mounjaro and Zepbound?
All three drugs came out of Lilly's labs, but they are meaningfully different molecules. Think of them as an evolution, not competitors.
Mounjaro / Zepbound (tirzepatide): Dual agonist targeting GIP and GLP-1. Approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Produces up to approximately 22.5% weight loss.
Retatrutide (LY3437943): Triple agonist targeting GIP, GLP-1, and glucagon. Still investigational. Phase 3 data shows up to 26.6% weight loss -- a noticeable step up.
The glucagon receptor adds direct increases in energy expenditure and fat burning. The GLP-1 and GIP components suppress appetite and slow gastric emptying. Together, they address weight from multiple biological angles at once.
For a detailed head-to-head breakdown, see: retatrutide vs semaglutide.
Current FDA Status: Where Things Stand in 2026
As of Q1 2026, retatrutide remains investigational -- meaning it is not FDA approved and not legally available as a prescription medication in the United States.
Lilly has not yet submitted an NDA for retatrutide, though the TRIUMPH trial data coming in through 2025--2026 sets up that filing. Based on current timelines:
| Milestone | Expected Timing |
|---|---|
| NDA submission | Late 2026 (after TRIUMPH-1 and TRIUMPH-2 data) |
| FDA review period | 6--12 months following acceptance |
| Potential approval | Late 2027 (realistic estimate); late 2026 under priority review |
This is later than some media coverage suggests. Several articles written in 2024 projected 2026 approval based on accelerated assumptions. With the dysesthesia signal now in the data and multiple TRIUMPH trials still reporting, the runway is longer than the optimistic case.
For a more detailed approval timeline, see our article on when will retatrutide be available.
What Approval Could Mean for Access and Cost
If you have watched the tirzepatide rollout, you already have a preview of what retatrutide's launch might look like -- and it is a mixed picture.
Pricing: Lilly priced Zepbound at around $1,059 per month list price without insurance. Based on inflation and retatrutide's positioning as a premium next-generation product, expect similar or slightly higher launch pricing. Out-of-pocket cost without insurance will be significant.
Insurance coverage: GLP-1 drugs for obesity have had a difficult relationship with insurers. Medicare still does not cover obesity-only GLP-1 prescriptions (it requires a covered comorbidity). Commercial insurance coverage is inconsistent. Lilly's Mounjaro/Zepbound experience gives them data to push back on denials.
Savings programs: Lilly has run savings card programs for Zepbound that bring costs under $200 per month for eligible commercially-insured patients. A similar program for retatrutide is likely.
Step therapy: Insurers will likely require patients to try cheaper options first -- meaning semaglutide or tirzepatide -- before approving retatrutide.
The bottom line: even with approval, access will not be immediate or equal. The same dynamics that made Zepbound difficult to obtain for many patients will apply here, at least initially.
Where Retatrutide Fits in Lilly's Pipeline
Retatrutide is not a standalone bet -- it is a key piece of Lilly's long-term strategy in the cardiometabolic drug market.
Lilly is also developing orforglipron, an oral GLP-1 pill, and exploring next-generation combinations beyond the triple agonist. They are simultaneously expanding indications for tirzepatide (heart failure, sleep apnea, NASH). The obesity drug market is projected to reach $100 billion annually by 2030, and Lilly intends to hold a major share of it.
Retatrutide's role in that picture: the premium injectable option for patients who need maximum efficacy -- those with severe obesity, multiple comorbidities, or who have not responded adequately to tirzepatide. It is not meant to replace Zepbound; it is meant to sit above it in the portfolio.
Frequently Asked Questions
Who manufactures retatrutide?
Eli Lilly and Company, headquartered in Indianapolis, Indiana, is the sole manufacturer and developer of retatrutide. The drug was developed entirely in-house as part of Lilly's GLP-1 research program, which also produced Mounjaro and Zepbound.
What is retatrutide brand name?
Retatrutide does not have an official brand name. Its research designation is LY3437943. A trademarked brand name will be announced when Lilly submits its NDA to the FDA, which has not happened as of early 2026.
Is retatrutide FDA approved?
No. Retatrutide is still an investigational drug as of 2026. Multiple Phase 3 TRIUMPH trials are underway or reporting data, but Lilly has not yet submitted an NDA. FDA approval is not expected before late 2026, with 2027 being the more realistic estimate.
How is retatrutide different from semaglutide and tirzepatide?
Semaglutide (Ozempic/Wegovy) is a single GLP-1 receptor agonist. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors. Retatrutide hits all three -- GLP-1, GIP, and glucagon receptors. That triple action appears to produce greater weight loss than either predecessor based on current clinical data.
What is the TRIUMPH program?
TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide, covering obesity, type 2 diabetes, cardiovascular disease, and osteoarthritis populations. As of early 2026, multiple TRIUMPH trials have reported positive topline results, with additional data expected through 2026.
How much weight loss does retatrutide cause?
Phase 3 TRIUMPH-4 results (Dec 2025) showed an average weight loss of up to 26.6% body weight on a placebo-adjusted basis, or up to 71.2 lbs on average at the highest dose. Phase 2 results showed 24.2% at 48 weeks. Both represent the highest efficacy numbers ever reported for an obesity drug in their respective trial phases.
Will retatrutide be covered by insurance?
There is no way to know for certain until it is approved and Lilly negotiates formulary placement. Based on the tirzepatide experience, initial coverage will be inconsistent -- especially for obesity without a listed comorbidity. Commercial insurers will likely require prior authorization and possibly step therapy. Medicare coverage for obesity-only indications remains a legislative question.
What is the official retatrutide brand name?
There is no official retatrutide brand name yet. Retatrutide's research designation is LY3437943. Eli Lilly will announce the commercial brand name when they file the New Drug Application with the FDA — that hasn't happened as of early 2026. For comparison: tirzepatide's brand names are Mounjaro (diabetes) and Zepbound (obesity); semaglutide's are Ozempic (diabetes) and Wegovy (obesity). When retatrutide reaches market, expect a similar two-brand structure for different indications. If you searched "what is retatrutide brand name", the short answer is: it doesn't have one yet — only the research code LY3437943 and the generic name retatrutide.
Where Things Stand Right Now
Retatrutide is Eli Lilly's drug, built on the same research foundation that produced two already-successful obesity medications. The retatrutide brand name does not exist yet, but the compound does -- and so does a growing body of Phase 3 evidence supporting it.
Lilly has demonstrated they can take a complex hormonal molecule from Phase 2 excitement to real-world prescription drug, twice. The TRIUMPH program is delivering results. The question is no longer whether retatrutide works -- the data is compelling -- but how long the regulatory path takes and whether the approval lands with a safety profile that insurers and patients can work with.
If you are thinking about future access, the best move is staying informed as TRIUMPH data rolls in and watching for Lilly's NDA announcement. That is when the timeline becomes real.
Want to explore more about this drug? Check out these related guides:
- What is retatrutide?
- When will retatrutide be available?
- Retatrutide vs semaglutide: how do they compare?
Currently researching peptides? Ascension Peptides offers rigorously tested research compounds with transparent lab verification.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide (LY3437943) is an investigational drug that has not received FDA approval. Do not attempt to obtain or use retatrutide outside of an approved clinical trial. Always consult a licensed healthcare provider before making any decisions about medications or weight management treatments. Eli Lilly has not reviewed or endorsed this content.
